JESSICA SCHMIDT: Open Payments
NPI 1205181005 · SANTA ROSA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,136 in 43 payments from 12 companies in 2025. Trend: 2023 $719 · 2024 $527 · 2025 $1,136
Food & beverage: $1,136
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $258 |
| ABBVIE INC. | 12 | $191 |
| Otsuka America Pharmaceutical, Inc. | 6 | $142 |
| Lundbeck LLC | 5 | $119 |
| Alkermes, Inc. | 4 | $106 |
| Axsome Therapeutics, Inc. | 5 | $106 |
| Teva Pharmaceuticals USA, Inc. | 2 | $74 |
| Almatica Pharma LLC | 2 | $35 |
| Janssen Pharmaceuticals, Inc | 1 | $33 |
| Biogen, Inc. | 1 | $28 |
Products named: REXULTI, CAPLYTA, VRAYLAR, ARISTADA, Auvelity, UZEDY, LOREEV XR, SPRAVATO.
Industry payments across CA — which companies pay providers there.
